| abstract |
The invention relates to compounds of formula (I), wherein A is an optionally substituted ring system, provided that the -CH(R?3)N(R2)B-R1¿ and -OR4 groups are positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the OR4 linking group (and therefore in the 3-position relative to the -CHR3NR2- linking group) is not substituted; B is an optionally substituted ring system: R1 is positioned on ring B in a 1,3 or 1,4 relationship with the -CH(R3)N(R2)- linking group and is as defined in the specification. R2 is hydrogen, C¿1-6?alkyl, optionally substituted by hydroxy, cyano or trifluoromethyl, C2-6alkenyl (provided the double bond is not in the 1-position), C2-6alkynyl (provided the triple bond is not in the 1-position), phenylC1-3alkyl or pyridylC1-3alkyl; R?3¿ is hydrogen, methyl or ethyl; R4 is optionally substituted: C¿1-6?alkyl, C3-7cycloalkylC1-3alkyl or C3-7cycloalkyl; and N-oxides of -NR?2¿ where chemically possible; and S-oxides of sulphur containing rings where chemically possible; and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. |